New drugs may have important yet underappreciated clinical consequences in patients requiring blood transfusion. Interference with routine methods for compatibility testing for blood transfusion puts ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved ID CORE XT, a molecular-based assay, to be used to determine blood compatibility prior to blood ...

(Nanowerk News) The provision of blood for patients who require repeated blood transfusions, as well as for individuals with rare blood types, presents an enormous challenge to transfusion services ...

(HealthDay)—The U.S. Food and Drug Administration has approved the ID CORE XT DNA-based test to help doctors verify blood compatibility before a transfusion. People who need repeated transfusions, ...

Grifols sCD38 is the industry's first-ever soluble recombinant protein designed to overcome the interference that the cancer therapy daratumumab has on critical blood-transfusion tests The solution ...